



•
CERTIFICATION OF ENROLLMENT
•

Study title:

A randomized, double-blind, placebo-controlled, parallel group, Phase 3 study, followed by open label extensions, to evaluate the efficacy of oral belumosudil in adult participants with chronic lung allograft dysfunction (CLAD) following bilateral lung transplantation.

EudraCT Number: 2023-503462-23
(hereinafter referred to as "Study")

Promoter: Sanofi S.r.l.
(hereinafter referred to as "Promoter")

The Promoter of the Study hereby certifies that the IRCCS ISMETT investigational site has enrolled a total of two (2) patients in the Study. Specifically, the first patient was enrolled in 2024, while the second patient was screened in December 2025 and randomized in 2026.

Date: 16 March 2026

Name: Giulia Boarin

Role: Clinical Operations Study Country Lead

Signature on behalf of the Promoter:

Giulia Boarin

Electronically signed by: Giulia Boarin
Reason: author of the document
Date: Mar 16, 2026 08:51:47 GMT+1